Cartalax — Research, Dosing & Price Guide

Cartalax is a Khavinson bioregulator tripeptide (Ala-Glu-Asp) targeting cartilage tissue and the musculoskeletal system. It promotes chondrocyte function, cartilage matrix synthesis, and the balance between cartilage degradation and regeneration. Used in Russian gerontological protocols to maintain joint integrity and counter age-related cartilage degeneration, it represents the bioregulatory approach to joint health.

Cartalax modulates gene expression in chondrocytes by interacting with tissue-specific chromatin regions. It influences the transcription of key cartilage matrix components including type II collagen, aggrecan, and cartilage oligomeric matrix protein (COMP). It also helps restore the balance between matrix metalloproteinases (MMPs — particularly MMP-13, the primary collagenase in cartilage degradation) and their tissue inhibitors (TIMPs), shifting the equilibrium from degradation toward synthesis. Additionally, Cartalax supports chondrocyte proliferative capacity and reduces the expression of senescence markers in aging cartilage cells, helping maintain the regenerative potential that declines with age.

• Khavinson Institute data demonstrated improved cartilage matrix synthesis markers (type II collagen, aggrecan) in aged cartilage tissue samples treated with Cartalax.
• Normalized chondrocyte proliferative capacity in aged tissue, shifting gene expression toward a younger phenotype.
• Short peptide sequences (2–4 amino acids) have been confirmed to interact with tissue-specific gene regulatory elements using molecular biology techniques (EMSA, ChIP assays).
• Part of the validated bioregulatory peptide family with 30+ years of clinical safety data in Russian gerontology practice.
• MMP/TIMP ratio normalization observed in treated cartilage cultures, suggesting anti-degenerative effects relevant to osteoarthritis.

• Standard dose: 10 mg subcutaneous injection daily.
• Typical cycle: 10–20 days.
• Repeat every 3–6 months for ongoing joint health maintenance.
• Often combined with BPC-157 for enhanced joint and connective tissue healing — Cartalax provides epigenetic cartilage support while BPC-157 provides growth factor and angiogenic support.
• Can be part of a comprehensive musculoskeletal bioregulator protocol alongside other tissue-specific peptides.
• No food timing restrictions. Inject subcutaneously in the abdomen or thigh.

Known Side Effects

• Injection site reactions — mild and uncommon.
• No significant adverse events in published literature.
• No systemic side effects reported — bioregulator peptides act through gentle epigenetic modulation.
• Short treatment cycles minimize any theoretical risks.
• No interactions with joint health supplements (glucosamine, chondroitin) or NSAIDs.

Safety Profile

Cartalax shares the excellent safety profile characteristic of all Khavinson bioregulator peptides. As a tripeptide, it is rapidly metabolized, non-immunogenic, and works through subtle epigenetic modulation. Decades of clinical use in elderly Russian populations — the primary demographic for joint degeneration — have not revealed safety concerns. It does not interact with NSAIDs, corticosteroids, or other joint-related medications. Contraindications are limited to known hypersensitivity and pregnancy/breastfeeding.

Days 1–10: No immediate subjective effects. Epigenetic modulation of chondrocyte gene expression is beginning at the molecular level. Days 11–20: The bioregulatory reset is establishing. Joint improvements are not typically perceptible during the treatment cycle itself. Weeks 3–12 (post-cycle): Benefits emerge gradually over the weeks following the cycle. Users may notice improved joint comfort, reduced morning stiffness, and better exercise tolerance. These subtle improvements reflect the restored cartilage matrix balance. Months 3–6: Effects persist for the inter-cycle period. Repeat cycles every 3–6 months maintain the benefits and provide cumulative improvement over multiple cycles.

Prices sourced from peptides.gg marketplace. Prices may vary.